Study of Diagnosis and Long-Term Treatment Outcomes in Adults with Primary Aldosteronism in Western Norway

What this Trial Is About

Researchers are studying patients with primary aldosteronism PA in Western and Mid-parts of Norway to understand the characteristics of these patients, the effects of PA on the heart before and after treatment, and long-term outcomes after treatment. The study includes a national registration of PA patients diagnosed or subtyped at Oslo University Hospital starting from 2022. This observational study aims to provide detailed information about PA and its treatment outcomes over time. Patients diagnosed with PA at Haukeland University Hospital since June 2013 are invited to join the study. Participants have baseline visits for clinical data registration and collection of blood and urine samples. A subgroup undergoes echocardiography before and one year after specific medical or surgical treatment for PA. Another subgroup participates in a cardiac MRI study using various imaging techniques including stress testing with adenosine, compared with healthy, age- and sex-matched controls. From 2025, PA patients diagnosed or subtyped at Oslo University Hospital will also be included. Participants attend regular follow-up visits after beginning treatment to monitor changes. The study measures long-term clinical and biochemical outcomes over five years, as well as heart function and structure using echocardiography and cardiac MRI over three years. Quality of life is also assessed. Healthy controls participate in the cardiac MRI substudy for comparison. The total participation time varies depending on the patients subgroup and assessments.

Primary Aldosteronism in Western Norway